TGFB1 and neoplasm: Certainly, peritumorally injected exosomes carrying immunomodulatory factors such as IL-12 and shRNA for TGF-β1 can take part in the reprogramming of suppressive TME and supporting the antitumor activity of peritumorally injected DC-based vaccines as well as reactivating endogenous immune cells arrested in a tumor nodule.